作者
Mohammad Reza Najafi, Mohammad Amin Najafi, Ramin Shayan-Moghadam, Zahra Saadatpour, Keyvan Ghadimi
发表日期
2020
期刊
American Journal of Clinical and Experimental Immunology
卷号
9
期号
4
页码范围
58
出版商
e-Century Publishing Corporation
简介
Background
Carbamazepine is a first line treatment for focal epilepsy. Tegretol and Tegatard are two trade name of Carbamazepine. Tegretol is produced by Novartis Pharmaceutical Company, Switzerland. Recently, Raha pharmaceutical Company in Iran has produced CBZ which trade named is Tegatard. Extended usage of Tegatard instead of Tegretol has economic benefits for Iranian families. In this clinical trial, we aimed to compare therapeutic efficacy and safety of Tegretol and Tegatard in patients suffering from focal seizures with or without secondary generalization.
Methods
200 patients with provoked or non-provoked focal seizure with or without secondary generalization were screened and 180 patients were fulfilled the criteria to enter this double blinded clinical trial study. Patients were divided into two groups, the first group (A) received Tegretol and the second group (B) Tegatard. Carbamazepine (CBZ …
引用总数
学术搜索中的文章